Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis

摘要: Liver transplantation is the only effective therapeutic option for patients with end-stage liver disease due to primary sclerosing cholangitis (PSC). In this study, we analyzed a single center's experience 150 consecutive PSC who received 174 allografts. Mean follow-up was 55 months. Actuarial patient survival at 1, 2, 5, and 10 years 93.7%, 92.2%, 86.4%, 69.8%, respectively, whereas graft 83.4%, 79.0%, 60.5%, respectively. The main indication retransplantation hepatic artery thrombosis, major cause of death severe infection. Patients had higher incidence acute cellular chronic ductopenic rejection compared non-PSC control group. Chronic adversely affected survival. Biliary strictures, both anastomotic nonanastomotic, were frequent occurred in 16.2% 27.2% patients, recurrent 20%. A negative impact on not seen either postoperative biliary strictures or recurrence PSC. Six (4%) cholangiocarcinoma 1 died related malignant disease. Seventy-eight percent associated inflammatory bowel disease, most commonly ulcerative colitis, which did outcome posttransplantation. Nine required proctocolectomy after transplantation; 5 because intractable symptoms 4 development colorectal carcinoma/high-grade dysplasia. Our data show that provides excellent long-term